Soleil Boughton Sells 3,236 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 3,236 shares of the company’s stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $27.77, for a total value of $89,863.72. Following the completion of the sale, the insider now owns 170,285 shares in the company, valued at approximately $4,728,814.45. This represents a 1.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, February 18th, Soleil Boughton sold 4,152 shares of Hims & Hers Health stock. The shares were sold at an average price of $60.69, for a total value of $251,984.88.
• On Monday, February 3rd, Soleil Boughton sold 4,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.30, for a total value of $146,600.90.
• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.90, for a total transaction of $1,619,174.70.
• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00.

Hims & Hers Health Price Performance

NYSE HIMS opened at $31.16 on Thursday. Hims & Hers Health, Inc. has a one year low of $11.20 and a one year high of $72.98. The firm has a market cap of $6.92 billion, a P/E ratio of 70.82 and a beta of 1.37. The stock’s 50-day moving average is $39.97 and its 200-day moving average is $29.79.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Crewe Advisors LLC acquired a new position in Hims & Hers Health during the 4th quarter worth approximately $28,000. Raleigh Capital Management Inc. boosted its holdings in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 1,100 shares during the last quarter. Blume Capital Management Inc. grew its position in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 600 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after buying an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC bought a new stake in Hims & Hers Health during the 4th quarter worth about $38,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Ratings Changes

HIMS has been the subject of several recent analyst reports. BTIG Research assumed coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective for the company. Citigroup reaffirmed a “sell” rating and set a $27.00 price target on shares of Hims & Hers Health in a report on Thursday, March 6th. Piper Sandler lifted their price target on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, February 25th. Morgan Stanley cut shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and raised their price objective for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Finally, Bank of America upped their price objective on Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a report on Tuesday, March 18th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $37.31.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.